The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LIX.g

Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

Publications

Abidi MZ, Haque J, Varma P, Olteanu H, Guru Murthy GS, Dhakal B, Hari P

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib.

Case reports in hematology 2016;2016;2389038 — 2016 — 2389038

Shamil E, Cunningham D, Wong BL, Jani P

Ruxolitinib Associated Tuberculosis Presenting as a Neck Lump.

Case reports in infectious diseases 2015;2015;284168 — 2015 — 284168

Chen YH, Lee CH, Pei SN

Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.

Leukemia & lymphoma 2015 May;56;1528-9 — 2015 May — 1528-9

Palandri F, Polverelli N, Catani L, Vianelli N

Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge.

Annals of hematology 2015 Mar;94;519-20 — 2015 Mar — 519-20

Hopman RK, Lawrence SJ, Oh ST

Disseminated tuberculosis associated with ruxolitinib.

Leukemia 2014 Aug;28;1750-1 — 2014 Aug — 1750-1

Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L, Tolomeo M

Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.

BMC research notes 2012 Oct 05;5;552 — 2012 Oct 05 — 552